Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CSTL
CSTL logo

CSTL Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Castle Biosciences Inc (CSTL) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
21.600
1 Day change
5.93%
52 Week Range
44.280
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Castle Biosciences (CSTL) is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 ready to deploy. The stock is showing some positive momentum and supportive analyst coverage, but the technical setup is mixed and there is no strong proprietary buy signal today. Since the user is unwilling to wait for an optimal entry point, I would still not call this an immediate buy; the better choice is to hold and wait for a clearer trend confirmation or a better entry.

Technical Analysis

CSTL closed at 22.55, up 4.00% on the day, which is constructive in the short term. MACD histogram is positive and expanding, indicating improving momentum. However, the moving averages are still bearish with SMA_200 > SMA_20 > SMA_5, which means the broader trend remains weak. RSI_6 at 70.236 is near overbought territory and does not provide a clean entry signal. Price is trading just above R1 (21.681) and below R2 (22.733), so the stock is testing near-term resistance rather than breaking into a strong trend. Overall, the short-term price action is improving, but the long-term technical trend is not yet fully reversed.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bullish. The put-call open interest ratio of 0.27 is low, showing more call positioning than put positioning. Option volume put-call ratio is 0.0, also signaling very strong call bias in today’s activity, though overall volume is light. Implied volatility is elevated at 76.89 with IV percentile 73.02, suggesting the market expects meaningful movement. This supports positive sentiment, but the thin option volume means the signal is more sentiment-based than conviction-based.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
4

Positive Catalysts

  • ["BTIG maintained a Buy rating and still sees asymmetric upside, while raising concern only by lowering target to $40 from $50.", "Canaccord also kept a Buy rating and highlighted solid operating momentum and multiple catalysts for long-term revenue growth.", "The company posted a solid 10% revenue beat in Q1, helped by robust volume growth in TissueCypher and DecisionDx-Melanoma.", "Options positioning is bullish, with a low put-call ratio and call-heavy activity.", "Recent price action is positive, with the stock up 4.00% on the day and showing improving MACD momentum."]

Neutral/Negative Catalysts

  • ["No news in the past week, so there is no fresh event-driven catalyst.", "Technical trend remains bearish at the medium-to-longer horizon because SMA_200 is above SMA_20 and SMA_5.", "RSI is near overbought, so the stock is not at an especially attractive pullback level.", "Analysts have lowered price targets from prior levels, which shows reduced valuation expectations even while maintaining Buy ratings.", "Hedge funds and insiders are neutral, with no meaningful buying signal from smart money.", "No recent congress trading data or influential figure trading activity was reported."]

Financial Performance

Financial snapshot data was not available due to an error, so the latest-quarter fundamentals cannot be fully assessed from the provided dataset. However, analyst commentary indicates Q1 was solid, with a 10% revenue beat driven by strong volume growth in TissueCypher and DecisionDx-Melanoma. The latest quarter referenced is Q1, and the growth trend appears positive on the top line.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent analyst sentiment remains constructive but slightly less aggressive on valuation. BTIG lowered its target to $40 from $50 while keeping a Buy rating, and Canaccord also lowered its target to $40 from $50 while keeping a Buy rating. The tone is still positive, with both firms pointing to operating momentum and long-term catalysts. The wall street view is more bullish than bearish, but the lowered targets show analysts are trimming upside expectations rather than becoming more optimistic.

Wall Street analysts forecast CSTL stock price to rise
5 Analyst Rating
Wall Street analysts forecast CSTL stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.600
sliders
Low
41
Averages
47.2
High
52
Current: 21.600
sliders
Low
41
Averages
47.2
High
52
KeyBanc
Overweight
downgrade
$50 -> $35
AI Analysis
2026-05-29
Reason
KeyBanc
Price Target
$50 -> $35
AI Analysis
2026-05-29
downgrade
Overweight
Reason
KeyBanc lowered the firm's price target on Castle Biosciences to $35 from $50 and keeps an Overweight rating on the shares.
BTIG
Buy
downgrade
$50 -> $40
2026-05-13
Reason
BTIG
Price Target
$50 -> $40
2026-05-13
downgrade
Buy
Reason
BTIG lowered the firm's price target on Castle Biosciences to $40 from $50 and keeps a Buy rating on the shares. The company delivered a solid 10% revenue beat in Q1 on the back of robust volume growth in TissueCypher and its DecisionDx-Melanoma test, respectively, both ahead of the firm's forecast. Asymmetric upside remains in shares of Castle, with SCC having been priced out of the stock for some time now, the firm added.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CSTL
Unlock Now

People Also Watch